O2h Ventures — Full Portfolio

Metrion Biosciences provides ion channel screening and drug discovery services for pharmaceutical and biotech companies.

BiotechDeep TechMedical DevicesCambridge, GB

Marc Rogers(Founding Director)inJohn Ford(Founding Director)inKeith McCullagh(Founding Director)inLee Patterson(Chief Executive Officer)in

Co-investorsGresham House VenturesMaven Capital Partners

Stratosvir develops engineered viral immunotherapy treatments for advanced cancers, including prostate cancer, using modified viruses to activate the body's immune system against tumors.

AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesStevenage, GB

Dr Chris Ullman(CEO)inAntonio Postigo(CSO)in

BoardPriya Mande(Chairman)in

Co-investorsDeep Science Ventures

Atelerix develops hypothermic hydrogel encapsulation technology that stabilises and preserves fresh cells, tissues, and blood at room temperature, eliminating the need for cryopreservation and cold-chain logistics.

BiotechMedical DevicesNew Materials

Steve Swioklo(Founder)in

Co-investorsCambridge Angels groupFuture Planet CapitalUK Innovation & Science Seed Fund

Enedra analyzes tumor evolution patterns by decoding convergent genomic signatures from cancer genomic data.

AI & Machine LearningBiotechMedical Devices

Co-investorsDeep Science VenturesKU Leuven Research & Development

The Financial Ombudsman Service is a free, statutory body set up by UK Parliament in 2001 to investigate and resolve complaints between consumers and financial businesses such as banks, insurers, and pension and investment providers.

FintechGovTechLegalTech

Co-investorsDeepbridge CapitalForce Over Mass CapitalFuel VenturesOxfordQVenturesSeneca Partners+1 more

Five Alarm Bio develops pharmaceutical compounds targeting a novel aging mechanism to prevent and treat age-related chronic diseases.

BiotechLongevity

William Bains(Founding scientist)in

Co-investorsCambridge Angels groupSyndicateRoom

BiotechDundee, Scotland

Timothy Jason Sparey(Executive Officer)Antoine Boulanger(Executive Officer)Francisca Peixoto(Executive Officer)Christopher Andrew Woodland(Executive Officer, Director)Mary Canning(Executive Officer)

Helus Pharma is a clinical-stage biopharmaceutical company developing small-molecule therapies for psychiatric and CNS conditions such as depression, anxiety, schizophrenia, and bipolar disorder.

BiotechHealthtechMental Health

Eric So(Co-Founder, Executive Chairman)inJohn Kanakis(Co-Founder)inPaul Glavine(Co-Founder and Chief Growth Officer)inMichael Halstead(Chief Executive Officer)inMichael Cola(Chief Executive Officer)Aaron Bartlone(Chief Operating Officer)in

o2h group is a life science and technology investment and innovation organization that co-invests, co-creates and co-executes new ideas, offering venture funds, co-working labs, and community programs.

BiotechDeep TechImpact & Social GoodAhmedabad, IN

PharmEnable applies AI to small molecule drug discovery, focusing on challenging and data-sparse biological targets that traditional methods struggle to address.

AI & Machine LearningBiotechDeep Tech

Hannah Sore(Founder)in

Co-investorsCambridge Angels groupMartlet CapitalMC Healthcare VenturesParkwalk AdvisorsWren Capital

PhoreMost is a biotechnology company developing small molecule drugs and targeted protein degradation therapeutics for cancers with high unmet clinical need, with a lead program (PMC-001) for primary and metastatic brain cancers in Phase 1/2a clinical evaluation.

BiotechMedical DevicesCambridge, GB

Co-investorsAmadeus Capital PartnersAstellas Venture Management LLCCambridge Angels groupUniversity of Cambridge EnterpriseAmadeus Capital SAParkwalk Advisors

London

Carol Routledge(Executive Officer)George Tziras(Director)Khalid Howladar(Director)Marie Claire Layzell(Executive Officer, Director)Peter Rands(Executive Officer, Director)

Spirea develops a multivalent ADC linker technology called ELIVATE that expands the range of usable payloads for antibody-drug conjugates, aiming to enable next-generation ADCs for oncology, inflammation, and autoimmune diseases.

BiotechDeep TechHealthtech

Myriam Ouberai(Founder)inBo Rode Hansen(Executive Director)in

Co-investorsCambridge Angels groupStart CodonACF InvestorsR42 Group

Stemnovate provides an integrated platform combining multiomics data, cell reprogramming technology, and mechanistic functional studies to accelerate drug discovery and clinical translation for rare diseases, neurodegenerative conditions, and other therapeutic areas across human and animal health.

AI & Machine LearningBiotechDeep Tech

Co-investorsCambridge Angels group